Trial of Low-Dose MTX and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2013 by University of Michigan Cancer Center
Information provided by (Responsible Party):
University of Michigan Cancer Center Identifier:
First received: July 5, 2011
Last updated: February 14, 2013
Last verified: February 2013

Patients with a type of non-Hodgkin lymphoma, called follicular lymphoma and have not yet had previous systemic treatment, such as chemotherapy or immunotherapy will be invited to participate. This research study is being conducted in order to evaluate the combination of lowdose methotrexate and 131I-tositumomab (Bexxar) with regards to whether the combination will reduce the occurrence of the HAMA (Human Anti-Mouse Antibody) response. HAMA is an immune reaction against the tositumomab protein. Symptoms arising from HAMA can range from a mild form, like a rash, to a more extreme and possibly life-threatening level. HAMA can also decrease the effectiveness of the treatment, or create a future reaction if a patient is given another treatment containing mouse antibodies. In addition to evaluating the occurrence of HAMA, this research study will also look at the short and long-term effectiveness of this combination in the treatment of lymphoma, as well as its safety.

Condition Intervention Phase
Follicular Lymphoma
Drug: Low dose methotrexate and Bexxar
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Trial of Low-Dose Methotrexate and Iodine I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma

Resource links provided by NLM:

Further study details as provided by University of Michigan Cancer Center:

Primary Outcome Measures:
  • determination of the rate of HAMA (human anti-mouse antibody) conversion following treatment [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Response rates. overall, complete, and partial response rates to this therapy. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • progression-free and overall survival rates [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 61
Study Start Date: July 2011
Estimated Study Completion Date: July 2017
Estimated Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment arm
Low dose methotrexate and Bexxar
Drug: Low dose methotrexate and Bexxar
131I-tositumomab (Bexxar) is a radioimmunotherapy (RIT) drug. RIT is a treatment strategy designed to target radiation specifically to cancer cells by attaching a radioactive atom to a monoclonal antibody, an immune system protein that binds to a particular protein. The 131I-tositumomab (Bexxar) therapeutic regimen is delivered in two sets of intravenous infusions given about 7 days apart. Nonradioactive Tositumomab is given before both the "dosimetric" infusion and the "therapeutic" infusion to improve distribution of these doses throughout the body. Methotrexate is an antifolate drug. It interferes with cells' ability to copy their DNA. This mainly affects cells that are dividing frequently, such as immune system cells and cancer cells. Methotrexate will be used in this study to try to prevent the occurrence of HAMA by limiting your body's ability to produce anti mouse antibodies.
Other Name: 131I-tositumomab

Detailed Description:

This is a single-arm, single institution, Phase II study to test the use of low-dose methotrexate in combination with I-131 tositumomab for its ability to lower the rate of (human anti-mouse antibody) HAMA formation in patients with previously untreated low-grade follicular lymphoma. Low-dose methotrexate will be given beginning 3 weeks prior to the first infusion of I-131 tositumomab (4 weekly doses) and continued for 6 weeks (10 total doses), the period of time during which the development of HAMA is most detrimental. A total of 61 patients will be enrolled. The primary endpoint of the study is the determination of the rate of HAMA conversion within the first seven weeks following treatment. The secondary endpoints include response rates, progression-free and overall survival, safety, and evaluation of the effect of methotrexate on blood lymphocyte subsets.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients must have a histologically-confirmed diagnosis of follicular non-Hodgkin's B-cell lymphoma, grade 1-2 (grade 1 or grade 2 by WHO classification prior to 2009).
  2. Patients must have Ann Arbor Stage III or IV extent of disease after complete staging.
  3. Patients must have a willingness and ability to follow prescribed radiation precautions
  4. Patients must not have had any previous treatment for low-grade lymphoma including chemotherapy or radiation. They may be newly diagnosed or observed without treatment after diagnosis. Symptomatic and asymptomatic patients will be eligible.
  5. Patients must have a performance status of 0-2 on the ECOG scale and an anticipated survival of at least 3 months.
  6. Patients must have an absolute neutrophil count >1500 cells/mm3 and a platelet count >100,000 cells/mm3 within 14 days of study entry. These blood counts must be sustained without support of hematopoietic cytokines or transfusion of blood products.
  7. Patients must have adequate renal function (defined as serum creatinine <2.0) and hepatic function (defined as total bilirubin <1.5 x ULN and AST <3 x ULN) within 14 days of study entry.
  8. Patients must have bi-dimensionally measurable disease. MRIT-II-003 May 18, 2011 Protocol Methotrexate & BEXXAR® (Tositumomab, Iodine I 131 Tositumomab) Page 5

Exclusion Criteria:

  1. Patients with follicular Grade 3a or 3b by WHO Classification.
  2. Patients with evidence of active infection requiring IV antibiotics at the time of study entry.
  3. Patients with New York Heart Association Class III or IV heart disease or other serious illness that would preclude evaluation.
  4. Patients with active obstructive hydronephrosis.
  5. Patients with prior malignancy other than lymphoma, except for adequately treated skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for 5 years.
  6. Patients with known HIV infection.
  7. Patients with known brain or leptomeningeal metastases.
  8. Patients who are pregnant or nursing. Patients of childbearing potential must undergo a pregnancy test within 7 days of study entry and methotrexate is not to be administered until a negative result is obtained. Males and females must agree to use effective contraception for 6 months following the radioimmunotherapy.
  9. Patients with previous allergic reactions to iodine. This does not include reacting to IV iodine-containing contrast materials.
  10. Patients with previous allergic reactions to methotrexate.
  11. Patients who were previously given any monoclonal antibody, regardless of species, for any condition.
  12. Detectable serum levels of HAMA.
  13. Patients who are concurrently receiving either approved or non-approved (through another protocol) anti-cancer drugs or biologics.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01389076

Contact: Cancer Answer Line 1-(800) 865 -1125

United States, Michigan
University of Michigan Recruiting
Ann Arbor, Michigan, United States, 48109
Contact: Daniel Lebovic, M.D.    734-936-5310   
Principal Investigator: Daniel Lebovic, M.D.         
Sponsors and Collaborators
University of Michigan Cancer Center
Principal Investigator: Daniel Lebovic, M.D. University of Michigan
  More Information

No publications provided

Responsible Party: University of Michigan Cancer Center Identifier: NCT01389076     History of Changes
Other Study ID Numbers: UMCC 2010.098, HUM00043235
Study First Received: July 5, 2011
Last Updated: February 14, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by University of Michigan Cancer Center:
Previously Untreated, Advanced-Stage, Follicular Lymphoma

Additional relevant MeSH terms:
Lymphoma, Follicular
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Iodine-131 anti-B1 antibody
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Pharmacologic Actions
Therapeutic Uses
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Immunosuppressive Agents
Immunologic Factors
Antirheumatic Agents
Nucleic Acid Synthesis Inhibitors processed this record on September 18, 2014